BeiGene Reports 627% Net Profit Jump in H1 2026, Revenue Up 26.84% to RMB22.22 Billion
BeiGene's net profit attributable to shareholders surged 627.15% year on year to RMB3.271 billion in the first half of 2026, while revenue rose 26.84% to RMB22.22 billion. Product revenue reached RMB21.797 billion, up from RMB17.36 billion a year earlier, driven by sales of Brukinsa (zanubrutinib), Amgen-licensed products, and Tevimbra (tislelizumab). Basic earnings per share were RMB2.26.
On August 26, BeiGene disclosed its interim report for the first half of 2026. The report shows that in the first half of 2026, the company achieved operating revenue of RMB22.22 billion, up 26.84% year on year; net profit attributable to shareholders of the listed company was RMB3.271 billion, up 627.15% year on year; basic earnings per share were RMB2.26.
During the reporting period, product revenue was RMB21.797 billion, compared with RMB17.36 billion in the same period of 2025. The growth in product revenue was mainly attributable to increased sales of Brukinsa (zanubrutinib), products licensed from Amgen, and Tevimbra (tislelizumab).
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 50/100 and 60% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.